Related Experiment Video
Updated: Aug 25, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Adjunctive therapies in the treatment of acute coronary syndromes
1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
Insights
Effective adjunctive therapies like aspirin and beta-blockers improve survival after myocardial infarction. However, these life-saving treatments are often underutilized, highlighting a gap in patient care and secondary prevention strategies.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Survival rates post-myocardial infarction (MI) have improved due to advanced medical treatments.
- Underutilization of evidence-based adjunctive therapies remains a significant clinical challenge.
- Optimizing secondary prevention is crucial for long-term patient outcomes after MI.
Purpose of the Study:
- To review current evidence supporting the use of essential adjunctive pharmacologic agents in acute myocardial infarction.
- To discuss the role of these agents in both acute treatment and long-term secondary prevention.
- To examine emerging and controversial pharmacologic therapies for MI management.
Main Methods:
- Literature review of clinical trials and guidelines.
- Analysis of pharmacologic agents proven to improve survival.
- Discussion of current clinical practice and future therapeutic directions.
Main Results:
- Established therapies including aspirin, beta-blockers, ACE inhibitors, and statins significantly enhance survival post-MI.
- These agents are vital for both acute management and secondary prevention.
- Evidence for certain emerging or controversial agents requires further investigation.
Conclusions:
- Consistent utilization of guideline-directed medical therapy is essential for improving MI survival.
- Addressing barriers to underutilization is critical for maximizing patient benefit.
- Ongoing research into novel pharmacotherapies may offer future advancements in MI care.
Abstract:
Survival after myocardial infarction has been improving steadily in recent decades, in part because of more effective adjunctive medical therapies. However, the issue of underutilization of effective medical therapies remains. Adjunctive therapy for acute myocardial infarction should include aspirin, beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and lipid-lowering agents, all of which improve survival in the treatment and secondary prevention of myocardial infarction. This review presents the current knowledge supporting the use of specific adjunctive pharmacologic agents and also discusses the current status of other agents that are emerging or controversial.
More Related Videos
05:58Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management
Angina IV: Management
Heart Failure VI: Adjunct Therapies